Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Tivicay

Tivicay 10 mg film-coated tablets Tivicay 25 mg film-coated tablets Tivicay 50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–10

HOS-129166 · Präparat HOS-096689

9 Magnesium/ Dolutegravir  Magnesium/ aluminium-containing antacid should aluminium-containing AUC  74% be taken well separated in time from the antacid Cmax  72% administration of dolutegravir (minimum 2 hours (Complex binding to after or 6 hours before). polyvalent ions) Calcium supplements Dolutegravir  - When taken with food, Tivicay and supplements (fasted intake) AUC  39% or multivitamins containing calcium, iron or Cmax  37% magnesium can be taken at the same time. C24  39% - If Tivicay is taken in a fasted state, such (Complex binding to supplements should be taken a minimum 2 hours polyvalent ions) after or 6 hours before the intake of Tivicay. Iron supplements Dolutegravir  (fasted intake) AUC  54% The stated reductions in dolutegravir exposure Cmax  57% were observed with the intake of dolutegravir and C24  56% these supplements during fasted conditions. In fed (Complex binding to state, the changes in exposure following intake polyvalent ions) together with calcium or iron supplements were Multivitamin Dolutegravir  modified by the food effect, resulting in an (containing calcium, AUC  33% exposure similar to that obtained with dolutegravir iron and magnesium) Cmax  35% administered in the fasted state. (fasted intake) C24  32% (Complex binding to polyvalent ions) Corticosteroids Prednisone Dolutegravir  No dose adjustment is necessary. AUC  11% Cmax  6% Cτ  17% Antidiabetics Metformin Metformin  A dose adjustment of metformin should be When co-administered with considered when starting and stopping dolutegravir 50mg once coadministration of dolutegravir with metformin, daily: to maintain glycaemic control. In patients with Metformin moderate renal impairment a dose adjustment of AUC  79% metformin should be considered when Cmax  66% coadministered with dolutegravir, because of the When co-administered with increased risk for lactic acidosis in patients with dolutegravir 50mg twice moderate renal impairment due to increased daily: metformin concentration (section 4.4). Metformin AUC  145 % Cmax  111% Antimycobacterials Rifampicin Dolutegravir  The recommended adult dose of dolutegravir is AUC  54% 50 mg twice daily when co-administered with Cmax  43% rifampicin in the absence of integrase class Cτ 72% resistance. In paediatric patients the weight-based (induction of UGT1A1 and once daily dose should be administered twice CYP3A enzymes) daily. In the presence of integrase class resistance this combination should be avoided (see section 4.4). Rifabutin Dolutegravir  No dose adjustment is necessary. AUC  5% Cmax  16% Cτ  30%

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262) calcium (HOS-085615) iron (HOS-085656) magnesium (HOS-085165) prednisone (HOS-084526) metformin (HOS-091032)